A5050549111- Breast Cancer Treatment Studies
- Advanced Radiotherapy Techniques
- Breast Lesions and Carcinomas
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Breast Implant and Reconstruction
- Brain Metastases and Treatment
- Cancer Treatment and Pharmacology
- Cardiac Arrhythmias and Treatments
- Lung Cancer Diagnosis and Treatment
- Management of metastatic bone disease
- Cardiac pacing and defibrillation studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Cardiac electrophysiology and arrhythmias
- Advances in Oncology and Radiotherapy
- Cancer Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Treatments and Mutations
- Medical Imaging Techniques and Applications
- Cancer Genomics and Diagnostics
- BRCA gene mutations in cancer
- Glioma Diagnosis and Treatment
- Lung Cancer Research Studies
- Effects of Radiation Exposure
University Hospital Schleswig-Holstein
2010-2025
University of Lübeck
2010-2025
Universitätsklinik für Strahlentherapie
2015-2025
Klinik und Poliklinik für Strahlentherapie und Radioonkologie
2015-2025
Universität Hamburg
2024-2025
University Medical Center Hamburg-Eppendorf
2024-2025
University Cancer Center Hamburg
2025
Heidelberg University
2015-2024
University Hospital Heidelberg
2015-2024
University of Rostock
2024
In clinically node-negative breast cancer patients, the INSEMA trial (NCT02466737) assessed non-inferiority of avoiding sentinel lymph node biopsy (SLNB) or axillary dissection (ALND). Here we present patient-reported outcomes (PROs) as a secondary endpoint.PROs were for patients with no surgery, SLNB alone, and ALND. Quality life (QoL) questionnaire EORTC QLQ-C30 its module (BR23) used at baseline (pre-surgery) 1, 3, 6, 12, 18 months after surgery. The QoL scores compared using repeated...
Abstract This yearʼs 18th St. Gallen (SG) consensus conference on the treatment of early breast cancer (SGBCC: International Breast Cancer Conference) focused practice-oriented questions. The individual situation and risk-benefit assessment were discussed in great detail. As previous years, a German working group leading experts presented results international SGBCC 2023 against background recommendations – especially updated Arbeitsgemeinschaft Gynäkologische Onkologie e. V. (AGO) for...
BackgroundWhether surgical axillary staging as part of breast-conserving therapy can be omitted without compromising survival has remained unclear.MethodsIn this prospective, randomized, noninferiority trial, we investigated the omission surgery compared with sentinel-lymph-node biopsy in patients clinically node-negative invasive breast cancer staged T1 or T2 (tumor size, ≤5 cm) who were scheduled to undergo surgery. We report here per-protocol analysis disease–free (the primary efficacy...
<b><i>Introduction:</i></b> Each year the interdisciplinary AGO (Arbeitsgemeinschaft Gynäkologische Onkologie, German Gynecological Oncology Group) Breast Committee on Diagnosis and Treatment of Cancer provides updated state-of-the-art recommendations for early metastatic breast cancer. <b><i>Methods:</i></b> The evidence-based treatment cancer have been released in March 2024. <b><i>Results Conclusion:</i></b> This...
Abstract Objective To update the practical guidelines for radiotherapy of patients with locoregional breast cancer recurrences based on current German interdisciplinary S3 2012. Methods A comprehensive survey literature using search phrases “locoregional recurrence”, “chest wall “local “regional and “breast cancer” was performed, limits “clinical trials”, “randomized “meta-analysis”, “systematic review”, “guidelines”. Conclusions Patients isolated in-breast or regional should be treated...
Abstract Background Single-session high-dose stereotactic radiotherapy (radiosurgery) is a new treatment option for otherwise untreatable patients suffering from refractory ventricular tachycardia (VT). In the initial single-center case studies and feasibility trials, cardiac radiosurgery has led to significant reductions of VT burden with limited toxicities. However, full safety profile remains largely unknown. Methods/design this multi-center, multi-platform clinical trial which we plan...